Live from the NIH registry
Studies recruiting near Fayetteville right now
Top 25 of 126 recruiting studies, sorted by proximity — each links to its official registry page
Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
Diffuse Large B-Cell Lymphoma, Grade 3b Follicular Lymphoma
Phase 2
Interventional 396 participants sought
Highlands Oncology Group - Fayetteville — Fayetteville, Arkansas (0.8 mi)
· Sponsor: SWOG Cancer Research Network
A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy
Locally Advanced Head and Neck Squamous Cell Carcinoma
Phase 3
Interventional 1,145 participants sought
Research Site — Springdale, Arkansas (8.2 mi)
· Sponsor: AstraZeneca
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
Metastatic Castration Sensitive Prostate Cancer (mCSPC), Hormone Sensitive Prostate Cancer
Phase 3
Interventional 1,000 participants sought
Highlands Oncology Group, PA — Fayetteville, Arkansas (0.8 mi)
· Sponsor: Pfizer
C-Brace Prospective Registry
Pareses, Lower Extremity
N/A
Observational 250 participants sought
Jonesboro P&O x Ottobock.care — Rogers, Arkansas (18.2 mi)
· Sponsor: Otto Bock Healthcare Products GmbH
Dental-Child Interaction Training
Behavior and Behavior Mechanisms, Child Behavior
N/A
Interventional 5,808 participants sought
University of Arkansas — Fayetteville, Arkansas (0.8 mi)
· Sponsor: University of Florida
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Advanced Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer
Phase 3
Interventional 1,410 participants sought
Highlands Oncology Group — Fayetteville, Arkansas (0.8 mi)
· Sponsor: Pfizer
Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma
Classic Follicular Lymphoma, Follicular Lymphoma With Unusual Cytological Features
Phase 3
Interventional 600 participants sought
Highlands Oncology Group - Fayetteville — Fayetteville, Arkansas (0.8 mi)
· Sponsor: National Cancer Institute (NCI)
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo
NonSegmental Vitiligo
Phase 3
Interventional 180 participants sought
Premier Dermatology Clinical Trials Institute At Northwest Arkansas — Fayetteville, Arkansas (0.8 mi)
· Sponsor: Incyte Corporation
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
Advanced Endometrial Carcinoma, Recurrent Endometrial Carcinoma
Phase 3
Interventional 255 participants sought
Highlands Oncology Group - Fayetteville — Fayetteville, Arkansas (0.8 mi)
· Sponsor: National Cancer Institute (NCI)
Efficacy of PP-01 in Mitigating Cannabis Withdrawal Symptoms in Adults With Cannabis Use Disorder
Cannabis Withdrawal
Phase 3
Interventional 420 participants sought
Woodland Research Northwest, LLC — Rogers, Arkansas (18.2 mi)
· Sponsor: PleoPharma, Inc.
Physical Activity and Community EmPOWERment Project
Intellectual Disability, Neurodevelopmental Disorders
N/A
Interventional 376 participants sought
University of Arkansas — Fayetteville, Arkansas (0.8 mi)
· Sponsor: University of North Carolina, Chapel Hill
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
Carcinoma, Non-Small-Cell Lung
Phase 3
Interventional 700 participants sought
Highlands Oncology Group — Springdale, Arkansas (8.2 mi)
· Sponsor: Eli Lilly and Company
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
Multiple Myeloma
Phase 3
Interventional 700 participants sought
Highlands Oncology Group — Springdale, Arkansas (8.2 mi)
· Sponsor: Janssen Research & Development, LLC
JAGUAR Trial: ObJective Analysis to GaUge EVAR Outcomes Through Randomization
AAA, AAA - Abdominal Aortic Aneurysm
N/A
Interventional 450 participants sought
Washington Regional Medical Center — Fayetteville, Arkansas (0.8 mi)
· Sponsor: Endologix
A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran With Nivolumab Versus Nivolumab Alone in Participants With High-risk Muscle-invasive Urothelial Carcinoma (MIUC)
Muscle-invasive Urothelial Carcinoma
Phase 2
Interventional 62 participants sought
Highlands Oncology Group. — Springdale, Arkansas (8.2 mi)
· Sponsor: Hoffmann-La Roche
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-2)
Bipolar Disorder Type I With Mania or Mania With Mixed Features
Phase 3
Interventional 274 participants sought
Woodland Research Northwest — Rogers, Arkansas (18.2 mi)
· Sponsor: Bristol-Myers Squibb
A First-in-Human Study of MEN2501 in Participants With Platinum-Resistant Ovarian Cancer
Platinum-resistant Ovarian Cancer
Phase 1
Interventional 100 participants sought
Highlands Oncology Group — Springdale, Arkansas (8.2 mi)
· Sponsor: Stemline Therapeutics, Inc.
Persona Revision Knee System Outcomes
Arthroplasty Complications, Infection
N/A
Observational 380 participants sought
Advanced Orthopaedic Specialists — Fayetteville, Arkansas (0.8 mi)
· Sponsor: Zimmer Biomet
GAINS Expert Guiding Technology to Coach Life Skill Teaching
GAINS Expert Guiding Technology to Coach Life Skill Teaching
N/A
Interventional 24 participants sought
University of Arkansas — Fayetteville, Arkansas (0.8 mi)
· Sponsor: Guiding Technologies Corporation
Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS)
Neovascular Age-Related Macular Degeneration (nAMD), Wet AMD
Phase 3
Interventional 284 participants sought
Adverum Clinical Site 198 — Springdale, Arkansas (8.2 mi)
· Sponsor: Adverum Biotechnologies, Inc.
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
Non-small Cell Lung Cancer
Phase 3
Interventional 1,160 participants sought
Research Site — Springdale, Arkansas (8.2 mi)
· Sponsor: AstraZeneca
A Study to Learn About How a New Pneumococcal Vaccine Works in Infants.
Pneumococcal Disease
Phase 3
Interventional 3,230 participants sought
Northwest Arkansas Pediatric Clinic — Fayetteville, Arkansas (0.8 mi)
· Sponsor: Pfizer
Parkinson's Foundation PD GENEration Genetic Registry
Parkinson's Disease
N/A
Observational 25,000 participants sought
University of Arkansas — Fayetteville, Arkansas (0.8 mi)
· Sponsor: Parkinson's Foundation
Lot-to-lot Consistency Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From 2 Months of Age
Pneumococcal Immunization, Healthy Volunteers
Phase 3
Interventional 2,195 participants sought
Northwest Arkansas Pediatric Clinic- Site Number : 8400039 — Fayetteville, Arkansas (0.8 mi)
· Sponsor: Sanofi
A Multi-site Study to Evaluate the Persistence of Protective Immunity to Routine Childhood Vaccinations in Participants With B-ALL/Ly Who Have Received Blinatumomab
B-Cell ALL, B-Cell Acute Lymphoblastic Leukaemia
N/A
Observational 300 participants sought
Arkansas Children's Northwest — Springdale, Arkansas (8.2 mi)
· Sponsor: Arkansas Children's Hospital Research Institute